An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma
Abstract Purpose To evaluate the clinical efficacy and safety of apatinib combined with intensity‐modulated radiation therapy (IMRT) in patients with unresectable hepatocellular carcinoma (uHCC). Materials and methods Open‐label, single‐arm, exploratory clinical trial of apatinib combined with IMRT...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4900 |
| _version_ | 1797950908368158720 |
|---|---|
| author | Hu Qiu Shaobo Ke Gaoke Cai Yong Wu Jin Wang Wei Shi Jiamei Chen Jin Peng Baoping Yu Yongshun Chen |
| author_facet | Hu Qiu Shaobo Ke Gaoke Cai Yong Wu Jin Wang Wei Shi Jiamei Chen Jin Peng Baoping Yu Yongshun Chen |
| author_sort | Hu Qiu |
| collection | DOAJ |
| description | Abstract Purpose To evaluate the clinical efficacy and safety of apatinib combined with intensity‐modulated radiation therapy (IMRT) in patients with unresectable hepatocellular carcinoma (uHCC). Materials and methods Open‐label, single‐arm, exploratory clinical trial of apatinib combined with IMRT for uHCC patients. Patients aged 18–75 years with adequate hematological, liver, and renal functions and Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 were enrolled in this study from March 2017 to September 2020. Patients were received IMRT (biological effective dose: 46–60 Gy) and continuous apatinib (250–500 mg/day) oral administration until HCC progression or unacceptable toxic effects. The endpoints included progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), objective response rate (ORR), and safety. The trial registration number is ChiCTR‐OPC‐17011890. Results A total of 33 patients have taken part in the study. The median age was 58 years old (range 32–77), 27 (81.9%) patients were ECOG PS 0–1, and 28 (84.9%) patients were male. In addition, 25 (75.7%) patients suffered from hepatitis B, 32 cases (97.0%) were in Barcelona Clinic Liver Cancer (BCLC) Stages B–C, and eight (24.2%) had portal vein involvement. Moreover, 12 (36.4%) and 21 (63.6%) patients received apatinib as first‐line and second or later‐line therapy, respectively. The average follow‐up was 11.4 months, the median PFS was 7.8 months (95% confidence interval: 3.9–11.7). The OS rates at 6 and 12 months were 96.7% and 66.2%. The ORR and DCR were 15.1% and 81.8%, respectively. Hepatic toxicity was the most common treatment‐related adverse events in Grades 3–4 (12.1%). No radiation‐induced liver disease and Grade 5 toxicity were recorded. Conclusion Apatinib combined with IMRT is a safe and effective method to improve PFS and DCR and has good anti‐tumor activity in patients with uHCC. |
| first_indexed | 2024-04-10T22:22:29Z |
| format | Article |
| id | doaj.art-e160f46dd6cc4a8cbd6159ee33073ba4 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-10T22:22:29Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-e160f46dd6cc4a8cbd6159ee33073ba42023-01-17T17:10:24ZengWileyCancer Medicine2045-76342023-01-0112121322210.1002/cam4.4900An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinomaHu Qiu0Shaobo Ke1Gaoke Cai2Yong Wu3Jin Wang4Wei Shi5Jiamei Chen6Jin Peng7Baoping Yu8Yongshun Chen9Department of Clinical Oncology Renmin Hospital of Wuhan University Wuhan ChinaDepartment of Clinical Oncology Renmin Hospital of Wuhan University Wuhan ChinaDepartment of Clinical Oncology Renmin Hospital of Wuhan University Wuhan ChinaDepartment of Clinical Oncology Renmin Hospital of Wuhan University Wuhan ChinaDepartment of Clinical Oncology Renmin Hospital of Wuhan University Wuhan ChinaDepartment of Clinical Oncology Renmin Hospital of Wuhan University Wuhan ChinaDepartment of Clinical Oncology Renmin Hospital of Wuhan University Wuhan ChinaDepartment of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan ChinaDepartment of Gastroenterology Renmin Hospital of Wuhan University Wuhan ChinaDepartment of Clinical Oncology Renmin Hospital of Wuhan University Wuhan ChinaAbstract Purpose To evaluate the clinical efficacy and safety of apatinib combined with intensity‐modulated radiation therapy (IMRT) in patients with unresectable hepatocellular carcinoma (uHCC). Materials and methods Open‐label, single‐arm, exploratory clinical trial of apatinib combined with IMRT for uHCC patients. Patients aged 18–75 years with adequate hematological, liver, and renal functions and Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 were enrolled in this study from March 2017 to September 2020. Patients were received IMRT (biological effective dose: 46–60 Gy) and continuous apatinib (250–500 mg/day) oral administration until HCC progression or unacceptable toxic effects. The endpoints included progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), objective response rate (ORR), and safety. The trial registration number is ChiCTR‐OPC‐17011890. Results A total of 33 patients have taken part in the study. The median age was 58 years old (range 32–77), 27 (81.9%) patients were ECOG PS 0–1, and 28 (84.9%) patients were male. In addition, 25 (75.7%) patients suffered from hepatitis B, 32 cases (97.0%) were in Barcelona Clinic Liver Cancer (BCLC) Stages B–C, and eight (24.2%) had portal vein involvement. Moreover, 12 (36.4%) and 21 (63.6%) patients received apatinib as first‐line and second or later‐line therapy, respectively. The average follow‐up was 11.4 months, the median PFS was 7.8 months (95% confidence interval: 3.9–11.7). The OS rates at 6 and 12 months were 96.7% and 66.2%. The ORR and DCR were 15.1% and 81.8%, respectively. Hepatic toxicity was the most common treatment‐related adverse events in Grades 3–4 (12.1%). No radiation‐induced liver disease and Grade 5 toxicity were recorded. Conclusion Apatinib combined with IMRT is a safe and effective method to improve PFS and DCR and has good anti‐tumor activity in patients with uHCC.https://doi.org/10.1002/cam4.4900apatinibhepatocellular carcinomaradiation therapyvascular endothelial growth factor |
| spellingShingle | Hu Qiu Shaobo Ke Gaoke Cai Yong Wu Jin Wang Wei Shi Jiamei Chen Jin Peng Baoping Yu Yongshun Chen An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma Cancer Medicine apatinib hepatocellular carcinoma radiation therapy vascular endothelial growth factor |
| title | An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma |
| title_full | An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma |
| title_fullStr | An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma |
| title_full_unstemmed | An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma |
| title_short | An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma |
| title_sort | exploratory clinical trial of apatinib combined with intensity modulated radiation therapy for patients with unresectable hepatocellular carcinoma |
| topic | apatinib hepatocellular carcinoma radiation therapy vascular endothelial growth factor |
| url | https://doi.org/10.1002/cam4.4900 |
| work_keys_str_mv | AT huqiu anexploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT shaoboke anexploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT gaokecai anexploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT yongwu anexploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT jinwang anexploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT weishi anexploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT jiameichen anexploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT jinpeng anexploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT baopingyu anexploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT yongshunchen anexploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT huqiu exploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT shaoboke exploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT gaokecai exploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT yongwu exploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT jinwang exploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT weishi exploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT jiameichen exploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT jinpeng exploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT baopingyu exploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma AT yongshunchen exploratoryclinicaltrialofapatinibcombinedwithintensitymodulatedradiationtherapyforpatientswithunresectablehepatocellularcarcinoma |